Compare Sterling Biotech with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs PANACEA BIOTECH - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH PANACEA BIOTECH STERLING BIOTECH/
PANACEA BIOTECH
 
P/E (TTM) x -0.4 12.2 - View Chart
P/BV x 0.0 2.9 0.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   PANACEA BIOTECH
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
PANACEA BIOTECH
Mar-18
STERLING BIOTECH/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs11364 2.9%   
Low Rs3129 2.6%   
Sales per share (Unadj.) Rs26.896.8 27.7%  
Earnings per share (Unadj.) Rs-15.0-12.4 120.5%  
Cash flow per share (Unadj.) Rs-5.5-2.9 191.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.950.4 108.9%  
Shares outstanding (eoy) m267.8761.25 437.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.5 10.2%   
Avg P/E ratio x-0.5-19.9 2.3%  
P/CF ratio (eoy) x-1.3-86.4 1.5%  
Price / Book Value ratio x0.14.9 2.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,86215,101 12.3%   
No. of employees `0001.42.5 54.9%   
Total wages/salary Rs m5471,516 36.1%   
Avg. sales/employee Rs Th5,303.32,401.9 220.8%   
Avg. wages/employee Rs Th403.8614.2 65.7%   
Avg. net profit/employee Rs Th-2,959.0-307.9 960.9%   
INCOME DATA
Net Sales Rs m7,1815,928 121.1%  
Other income Rs m4382 51.8%   
Total revenues Rs m7,2236,010 120.2%   
Gross profit Rs m947845 112.0%  
Depreciation Rs m2,543585 434.5%   
Interest Rs m4,3771,006 435.2%   
Profit before tax Rs m-5,931-664 893.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,92499 -1,951.6%   
Profit after tax Rs m-4,007-760 527.2%  
Gross profit margin %13.214.3 92.5%  
Effective tax rate %32.4-14.9 -218.3%   
Net profit margin %-55.8-12.8 435.2%  
BALANCE SHEET DATA
Current assets Rs m14,3355,603 255.8%   
Current liabilities Rs m49,8096,910 720.8%   
Net working cap to sales %-494.0-22.0 2,241.1%  
Current ratio x0.30.8 35.5%  
Inventory Days Days403206 196.0%  
Debtors Days Days17184 203.8%  
Net fixed assets Rs m55,4329,941 557.6%   
Share capital Rs m26861 437.0%   
"Free" reserves Rs m13,9353,026 460.6%   
Net worth Rs m14,7013,087 476.2%   
Long term debt Rs m9,4785,707 166.1%   
Total assets Rs m73,98816,076 460.3%  
Interest coverage x-0.40.3 -104.3%   
Debt to equity ratio x0.61.8 34.9%  
Sales to assets ratio x0.10.4 26.3%   
Return on assets %0.51.5 32.8%  
Return on equity %-27.3-24.6 110.7%  
Return on capital %-6.43.9 -164.1%  
Exports to sales %25.924.0 107.8%   
Imports to sales %0.217.5 1.0%   
Exports (fob) Rs m1,8601,424 130.6%   
Imports (cif) Rs m121,040 1.2%   
Fx inflow Rs m1,8601,600 116.2%   
Fx outflow Rs m251,131 2.2%   
Net fx Rs m1,835469 391.6%   
CASH FLOW
From Operations Rs m1,7191,180 145.6%  
From Investments Rs m-3,148553 -569.4%  
From Financial Activity Rs m1,426-1,644 -86.8%  
Net Cashflow Rs m-390 -3.8%  

Share Holding

Indian Promoters % 33.9 74.5 45.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 9.9 1.3 761.5%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 23.6 166.5%  
Shareholders   21,482 10,259 209.4%  
Pledged promoter(s) holding % 55.9 35.1 159.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS